Navigation Links
The BioProcess International October Issue - Now Available in Print, Digital and Mobile App Editions

New York, NY (PRWEB) October 31, 2013

BioProcess International announces the publication of the BioProcess International October 2013 issue featuring the following articles and special reports:

Focus on Purification

Membrane adsorbers are the fastest-growing segment of single-use bioprocessing. But in this article, Eric Langer reports on results from the latest BioPlan Associates survey on biopharmaceutical manufacturing showing that membrane adsorbers are still among the least-adopted disposable devices. With input from makers and users, he addresses the question of how and whether such technology can revolutionize bioprocessing.

Focus on the Regs

In 2013, the European Medicines Agency (EMA) issued two guidance documents addressing production and quality control using bovine serum and porcine trypsin. In this article, Martin Wisher’s first installment of a quarterly regulatory series looks at key points of those new guidances, which define expected approaches for minimizing the risk of virus contamination when using such animal-derived raw materials.

Focus on Outsourcing

Biopharmaceuticals present much opportunity to contract manufacturers. But they must harmonize and seamlessly integrate their quality systems with regulatory requirements and client expectations. In this article, three authors from Kemwell Biopharma describe structural and manufacturing complexities, quality challenges, regulatory concerns, and strategies for meeting requirements of clients around the globe.

BPI Lab: Cell Signaling

Cell signaling and signal transduction allow cells to perceive and correctly respond to their environment. Understanding cellular communication is vital to bioengineering and disease treatment. In this article, senior technical editor Cheryl Scott explores some history, commonly used analytical methods, and reasons for studying cell signaling in biopharmaceutical development.

Challenging Protein A

Financial opportunities are driving many technology developers to try replacing protein A, but users are growing less motivated to implement alternatives that offer only incremental improvements. For an alternative technology to seriously challenge protein A’s dominance in the antibody-purification market, simple replacement will not be enough. As Pete Gagnon describes, it will need to offer a true paradigm shift. And a few such candidates are now emerging.

New Approaches to Process Validation

The new process validation guidance asks companies in the United States and Europe to adopt life-cycle approaches — beyond the traditional three-to-five lots run at the center point of proposed ranges for operating parameters. In this article, a consensus paper from the January 2013 CMC Strategy Forum addresses how companies can leverage product design and process development information to facilitate adapting the Quality by Design paradigm more closely — allowing for a science- and risk-based selection of critical process parameters, key process indicators, and appropriate specification criteria.

Also published this month as part of the BioProcess International Supplement Series - Vaccines: New Tools and Technologies for an Expanding Industry

Also Available Online-only in the BPI Extra section of

Ask the Expert: The Future of Protein A

BPI’s managing editor Maribel Rios talked with Karol Lacki (staff scientist at GE Healthcare Biosciences) about the use and future of protein A in bioprocessing. Its selectivity, robustness, and well-known ability to bind to a wide range of IgG molecules have made protein A a widely accepted affinity resin for current purification streams. Nonetheless, the industry has raised some concerns over cost, productivity, and other issues. That has led to the development of novel alternatives for purification that reportedly offer advantages over protein A. Lacki discuses the impact of those systems, pointing out their specific disadvantages that should be taken under consideration. In addition, he argues that the cost of protein A may be “misrepresented.” Finally, Lacki believes “smart engineering approaches” to the use of resins will be the next trend in efficient chomatography.

Best of BPI - Revisted: Virological Safety of Biopharmaceuticals

In an audiocast with managing editor Maribel Rios, Hazel Aranha (manager of viral clearance and safety at Catalent Pharma Solutions) discusses risk assessment and management strategies since her November 2005 article, “Virological Safety of Biopharmaceuticals.” Several factors have made risk an increasingly important issue, including the globalization of the industry and concerns over emerging viruses. Some strategies for addressing risk — such as the “as low as is reasonably practicable” (ALARP) approach and conducting a cost–benefit and decision analysis — are still appropriate. ICH has developed risk-related documents, including Q9, Q10, and Q11. Aranha discusses the effects of those guidelines on risk mitigation. She also talks about how increased collaboration between industry and regulatory groups and between industry and suppliers will be a major part of the bioprocessing industry in the next five years.

View the latest issue of BioProcess International online at:

Also available on the BioProcess International mobile app for iPad and iPhone by searching the App Store for “BioProcess International” or visiting:

Request your own subscription to the print journal at:

About BioProcess International

BioProcess International™ ( is a monthly, controlled-circulation magazine devoted to the development, scale-up, and manufacture of biotherapeutics and biodiagnostics. Each issue provides the global industrial biotherapeutic community with up-to-date, peer-reviewed information detailing the business, politics, ethics, applications, products, and services required to successfully drive biopharmaceuticals, vaccines, and biodiagnostics through the development and manufacturing process.

BioProcess International™ is part of the IBC Life Sciences Division of Informa, plc, a leading international provider of specialist information and services for the academic, professional and business communities. Informa offers a world-class portfolio of publications, events and data services for researchers, students, lecturers and professionals in the academic and scientific communities worldwide.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA
2. BioProcess International March 2013 Issue Published on the App Store Featuring App-only Exclusive Content
3. Life Technologies Acquires BAC BV, Expands Capabilities in Bioprocessing
4. BioProcess International December 2012 Issue Now Available on the App Store for iPad and iPhone
5. BioStorage Technologies Expands its Service Offering to Include Advanced Bioprocessing Solutions
6. Russias International Biotechnology Center Generium Signs Access Agreement to Elseviers ScienceDirect and Embase
7. BioTechniques: The International Journal of Life Science Methods Announces the Publication of the October 2013 Digital Edition Now Available Online and in the App Store
8. PAREXEL International Reports First Quarter Fiscal Year 2014 Results
9. CA BOTANA International New Peptide Formulations
10. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
11. Dr. Rongxiang Xu wird während seiner Auszeichnung mit dem internationalen Golden Biatec 2013 erklären, wie sich menschliche Organe selbst regenerieren können
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015  Symic, a clinical-stage biotherapeutics company ... matrix (ECM), today announced that it has secured $25 ... company,s pipeline, including its lead candidates SB-030 and SB-061. ... the participation by all existing major investors, as well ... total capital raised by Symic to over $43 million ...
(Date:12/1/2015)... ... ... Matthew “Tex” VerMilyea, PhD, HCLD, has joined Texas Fertility Center as its ... procedures as well as continue his research efforts into the emerging technologies of embryo ... Zealand to bring home a High Complexity Clinical Laboratory Director named Tex,” says ...
(Date:11/30/2015)... ... , ... Global Stem Cells Group today announced ... Marriott. The Global Stem Cells Group GMP facility is equipped with the most ... researchers and practitioners, experienced in administering stem cell protocols using highly manipulated cells. ...
(Date:11/30/2015)... Partnership includes an MPP ... the u niversity , s Solid Drug Nanoparticle ... cale - up through cost ... , where licensees based anywhere in the world will have the right to ... Africa , where licensees based anywhere in the world will have the ...
Breaking Biology Technology:
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/11/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology company ... to announce that it will be a Sponsor of the ... be held November 17-19 in Hamburg , ... iMedNet , MedNet,s easy-to-use, proven and affordable ... been able to deliver time and cost savings of up ...
(Date:11/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... broader entry into the automotive market with a comprehensive ... pace of consumer electronics human interface innovation. Synaptics, industry-leading ... for the automotive industry and will be implemented in ... Europe , Japan , and ...
Breaking Biology News(10 mins):